Adagrasib for previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer (terminated appraisal)

  • Technology appraisal
  • TA1076
  • Published: 
Following a request from the company to review the appraisal timelines the second committee meeting will now no longer take place on Thursday 12 June.